Greenbrook TMS Announces Results of Voting at Annual Meeting of Shareholders

$GBNH
Misc Health and Biotechnology Services
Health Care
Get the next $GBNH alert in real time by email

Greenbrook TMS Inc. (TSX:GTMS, NASDAQ:GBNH) ("Greenbrook" or the "Company"), a leading provider of Transcranial Magnetic Stimulation ("TMS") therapy in the United States, announced today the results of voting at its annual meeting of shareholders held earlier today (the "Meeting"). Each of the matters voted upon at the Meeting as set out below is described in greater detail in the Notice of Annual Meeting of Shareholders and Management Information Circular of Greenbrook dated May 11, 2022 (the "Circular").

The total number of common shares represented at the Meeting was 10,711,474, representing approximately 60.17% of Greenbrook's outstanding common shares entitled to be voted.

Election of Directors

All of the nominees listed in the Management Information Circular of Greenbrook prepared in connection with the Meeting were elected as directors by a resolution passed by a majority of the shareholders represented in person or by proxy at the Meeting, to hold office until the next annual meeting following their election or until their successors are elected or appointed. The following represents the votes received with regard to such matter:

Nominee

Votes For

% Votes For

Votes Withheld

% Votes Withheld

Brian P. Burke

9,966,607

99.97%

2,873

0.03%

Colleen Campbell

9,969,379

100.00%

101

0.00%

Sasha Cucuz

9,969,391

100.00%

89

0.00%

Adrienne Graves, Ph.D.

9,963,591

99.94%

5,889

0.06%

Robert Higgins

9,966,307

99.97%

3,173

0.03%

Bill Leonard

9,969,167

100.00%

313

0.00%

Adele C. Oliva

9,969,391

100.00%

89

0.00%

Frank Tworecke

9,966,218

99.97%

3,262

0.03%

Elias Vamvakas

9,969,378

100.00%

102

0.00%

Appointment of Auditors

KPMG LLP was reappointed as auditor of Greenbrook and the directors were authorized to fix the auditor's remuneration by a resolution passed by a majority of the shareholders represented in person or by proxy at the Meeting. The following represents the votes received with regard to such matter:

Votes For

% Votes For

Votes Withheld

% Votes Withheld

10,711,174

100.00%

300

0.00%

About Greenbrook TMS Inc.

Operating through 148 Company-operated treatment centers, Greenbrook is a leading provider of TMS therapy, an FDA-cleared, non-invasive therapy for the treatment of Major Depressive Disorder and other mental health disorders, in the United States. TMS therapy provides local electromagnetic stimulation to specific brain regions known to be directly associated with mood regulation. Greenbrook has provided more than 840,000 TMS treatments to over 24,000 patients struggling with depression.

Get the next $GBNH alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$GBNH

DatePrice TargetRatingAnalyst
More analyst ratings

$GBNH
Press Releases

Fastest customizable press release news feed in the world

See more
  • Greybrook Announces Passing of Founder Elias Vamvakas

    TORONTO, July 11, 2024 /CNW/ - It is with heavy hearts that the Executive Team at Greybrook announces the passing of our cherished founder, Elias Vamvakas, today, after a courageous battle with pancreatic cancer. Elias was 65 years old. Elias Vamvakas was a visionary leader whose entrepreneurial spirit and dedication laid the foundation for Greybrook, a distinguished Canadian private equity firm with investments in real estate and health care. Born in 1958 in Athens, Greece, Elias immigrated to Canada in 1966. His journey from an immigrant to a celebrated business leader was a

    $GBNH
    Misc Health and Biotechnology Services
    Health Care
  • GREENBROOK TMS ANNOUNCES DELISTING FROM NASDAQ

    TORONTO, Feb. 23, 2024 /PRNewswire/ - Greenbrook TMS Inc. (NASDAQ:GBNH) ("Greenbrook" or the "Company") today announced receipt of the final delisting notice from the Listing Qualifications Department of the Nasdaq Stock Market LLC ("Nasdaq") due to the continued failure to satisfy either the $1.00 minimum bid price listing requirement in Nasdaq Listing Rule 5550(a)(2) or the minimum stockholders' equity requirements in Nasdaq Listing Rule 5550(b). Nasdaq has notified the Company that trading of its common shares (the "Common Shares") will be suspended as of the open of trading on February 26, 2024. After careful consideration, the Company determined that it was in the overall best interests

    $GBNH
    Misc Health and Biotechnology Services
    Health Care
  • Greenbrook Announces $1.2 Million Registered Direct Offering

    TORONTO, Feb. 22, 2024 /PRNewswire/ - Greenbrook TMS Inc. (NASDAQ:GBNH) ("Greenbrook" or the "Company"), today announced that it has entered into securities purchase agreements with  institutional investors for the purchase and sale of 6,000,000 common shares at a purchase price of $0.20 per share pursuant to a registered direct offering, resulting in gross proceeds of approximately $1.2 million before deducting placement agent commissions and other estimated offering expenses. The closing of the offering is expected to occur on or about February 26, 2024, subject to the satisfaction of customary closing conditions. The Company intends to use the net proceeds for working capital as well as

    $GBNH
    Misc Health and Biotechnology Services
    Health Care

$GBNH
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$GBNH
SEC Filings

See more

$GBNH
Leadership Updates

Live Leadership Updates

See more
  • GREENBROOK APPOINTS PETER WILLETT AS CHIEF FINANCIAL OFFICER

    TORONTO, Jan. 29, 2024 /PRNewswire/ - Greenbrook TMS Inc. (NASDAQ:GBNH) ("Greenbrook" or the "Company") today announced that the Company's Board of Directors has appointed Mr. Peter Willett as the Company's full-time Chief Financial Officer, effective immediately. Mr. Willett was appointed Interim Chief Financial Officer of the Company in October 2023, prior to which he has been a key player on the Greenbrook finance team over the past six years, serving as its Senior Vice President of Finance. Peter brings over 11 years of finance experience, providing a broad base of experience and specialized knowledge about the financial and accounting matters that are unique to the mental health servic

    $GBNH
    Misc Health and Biotechnology Services
    Health Care
  • GREENBROOK TMS ANNOUNCES DIRECTOR APPOINTMENT

    TORONTO, Jan. 23, 2024 /PRNewswire/ - Greenbrook TMS Inc. (NASDAQ:GBNH) ("Greenbrook" or the "Company") today announced that it has appointed Ms. Juliana Elstad to the Company's board of directors as an independent director, effective immediately. Ms. Elstad has also been appointed to the Company's Governance and Nominating Committee. Juliana Elstad is a CEO, entrepreneur, and advisor with over 20 years of experience bringing medical innovation to patients and delivering success in small startup to multi-billion-dollar environments. She has a proven track record of creating, growing, and leading medical technology organizations with a focus on building dynamic cultures and mentoring high-po

    $GBNH
    Misc Health and Biotechnology Services
    Health Care
  • GREENBROOK TMS ANNOUNCES RESULTS OF VOTING AT ANNUAL MEETING OF SHAREHOLDERS

    TORONTO, June 20, 2023 /PRNewswire/ - Greenbrook TMS Inc. (NASDAQ:GBNH) ("Greenbrook" or the "Company"), a leading provider of Transcranial Magnetic Stimulation ("TMS") therapy in the United States, announced today the results of voting at its annual meeting of shareholders held earlier today (the "Meeting"). Each of the matters voted upon at the Meeting as set out below is described in greater detail in the Notice of Annual Meeting of Shareholders and Management Information Circular of Greenbrook dated May 11, 2023 (the "Circular").   The total number of common shares represented at the Meeting was 29,769,721, representing approximately 72.96% of Greenbrook's outstanding common shares entit

    $GBNH
    Misc Health and Biotechnology Services
    Health Care

$GBNH
Financials

Live finance-specific insights

See more
  • GREENBROOK TMS ANNOUNCES DELISTING FROM NASDAQ

    TORONTO, Feb. 23, 2024 /PRNewswire/ - Greenbrook TMS Inc. (NASDAQ:GBNH) ("Greenbrook" or the "Company") today announced receipt of the final delisting notice from the Listing Qualifications Department of the Nasdaq Stock Market LLC ("Nasdaq") due to the continued failure to satisfy either the $1.00 minimum bid price listing requirement in Nasdaq Listing Rule 5550(a)(2) or the minimum stockholders' equity requirements in Nasdaq Listing Rule 5550(b). Nasdaq has notified the Company that trading of its common shares (the "Common Shares") will be suspended as of the open of trading on February 26, 2024. After careful consideration, the Company determined that it was in the overall best interests

    $GBNH
    Misc Health and Biotechnology Services
    Health Care
  • GREENBROOK TMS RAISES US$2.5 MILLION IN DEBT FINANCING

    TORONTO, Feb. 15, 2024 /PRNewswire/ - Greenbrook TMS Inc. (NASDAQ:GBNH) ("Greenbrook" or the "Company") today announced that it has entered into the twenty-fifth amendment (the "Amendment") to the Company's credit facility (the "Credit Facility") with affiliates of Madryn Asset Management, LP ("Madryn"). As part of the Amendment, the Company secured an additional US$2,538,071 in senior secured term loans from Madryn under the Credit Facility (the "New Loan"). After giving effect to the New Loan, the Company has an aggregate amount of approximately US$87 million outstanding under the Credit Facility. The proceeds of the New Loan are expected to be used by the Company for general corporate an

    $GBNH
    Misc Health and Biotechnology Services
    Health Care
  • GREENBROOK TMS RAISES US$1.5 MILLION IN DEBT FINANCING

    TORONTO, Feb. 6, 2024 /PRNewswire/ - Greenbrook TMS Inc. (NASDAQ:GBNH) ("Greenbrook" or the "Company") today announced that it has entered into the twenty-fourth amendment (the "Amendment") to the Company's credit facility (the "Credit Facility") with affiliates of Madryn Asset Management, LP ("Madryn"). As part of the Amendment, the Company secured an additional US$1,522,843 in senior secured term loans from Madryn under the Credit Facility (the "New Loan"). After giving effect to the New Loan, the Company has an aggregate amount of approximately US$85 million outstanding under the Credit Facility. The proceeds of the New Loan are expected to be used by the Company for general corporate an

    $GBNH
    Misc Health and Biotechnology Services
    Health Care

$GBNH
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more